# Transcription factor AP-4 is a ligand for immunoglobulin- $\kappa$ promoter E-box elements

Alaitz ARANBURU<sup>1</sup>, Robert CARLSSON, Christine PERSSON and Tomas LEANDERSON

Section for Immunology, Department of Cell and Molecular Biology, Lund University, BMC I13, S-22184 Lund, Sweden

Immunoglobulin (Ig)- $\kappa$  promoters from humans and mice share conserved sequences. The octamer element is common to all Ig promoters and pivotal for their function. However, other conserved sequence motifs, that differ between Ig variable gene families, are required for normal promoter function. These conserved motifs do not stimulate transcription in the absence of an octamer. One example is an E-box of the E47/E12 type (5'-CAGCTG-3'), which is found in all promoters of the human and murine Ig- $\kappa$  gene subgroups/families, with the exception of subgroups II and VI and their related murine families. In the present study we show that the ubiquitously expressed transcription factor AP-4, and not E47, interacts specifically with the

### INTRODUCTION

Immunoglobulin (Ig)- $\kappa$  V gene sequences from humans and mice have been classified into a number of subgroups and families, respectively, according to sequence similarities in their coding regions [1,2]. However,  $V\kappa$  gene conservation also extends into the promoter regions. Although the octamer motif and the TATA box are the only elements that are conserved in all  $V\kappa$ promoters, other elements are conserved within different subgroups and families [3,4]. The octamer interacts with the Oct family of transcription factors [5]. It is essential for the normal function of Ig promoters, since mutations in the octamer that abrogate Oct binding result in levels of transcription similar to those observed with a TATA box only [6-8]. However, a minimal Ig promoter containing an octamer as the sole upstream element can only stimulate 10-20% of the transcriptional activity seen with an intact  $\kappa$  promoter [7,9]. Hence,  $\kappa$  promoters are dependent on additional functional DNA elements for full activity [9,10]. These co-stimulatory elements, however, are not capable of stimulating transcription by themselves but are strictly dependent on the presence of an octamer element for activity. Thus  $\kappa$ promoter function is based on functional modularity [10].

Some of the co-stimulatory DNA elements are conserved within V $\kappa$  subgroups/families and between species, and some are not [4]. Examples of the former are the E-box motifs that are conserved within the human V $\kappa$  subgroups I, III, IV, V and VII and the related murine families, and the CCCT motif that is conserved within the human V $\kappa$  II subgroup and its related murine families [4]. Interestingly, the majority of the E-boxes found in V $\kappa$  promoters are of the E2A type (5'-CAGNTG-3')5'-CANCTG-3') [4], indicating that they are potential recognition sites for the *E2A* gene products E47 and E12 [11]. However, this represents a paradox, since the *E2A* gene products are intrinsically potent activators of transcription [12–14]. Previous studies have indicated that basic helix–loop–helix (bHLH) proteins interact *in vitro* with  $\kappa$  promoter E-boxes [15,16]. However, E47, although  $\kappa$  promoter E-boxes when tested in electrophoretic mobility-shift assays using nuclear extracts derived from human and murine Bcell lines. Furthermore, AP-4, unlike E47, did not act as a transactivator, which is in agreement with previous studies on intact  $\kappa$  promoters, showing that transcription is absent when the octamer element has been mutated. Based on these data, and the conservation of the 5'-CAGCTG-3' motif among human and murine  $\kappa$  promoters, we propose that AP-4 is the major ligand for Ig- $\kappa$  promoter E-boxes.

Key words: bHLH-Zip protein, conserved sequences, immunoglobulin genes.

reported to bind optimally to the E-box sequence 5'-CAGCTG-3' [17], interacted poorly with  $\kappa$ -promoter E-boxes [18], indicating that some other bHLH protein might be the E-box binding factor.

AP-4 is a ubiquitously expressed transcription factor of the bHLH-Zip subgroup of bHLH proteins, that binds the 5'-CAGCTG-3' motif [19]. It was first identified as a factor binding to the simian virus (SV)40 enhancer, and was shown to interact synergistically with AP-1 to increase transcription in vitro from the SV40 late promoter [20]. Dimerization of bHLH proteins through the helix-loop-helix domain is a prerequisite for specific DNA binding via a short region of basic residues. In addition, bHLH-Zip proteins possess a second dimerization domain, the leucine zipper [21]. AP-4 is unique in that it contains an additional leucine zipper. Hence, AP-4 presents a specific tripartite dimerization structure, suggesting that AP-4 may interact with a wide variety of transcription factors [19]. However, there are no known heterodimerization partners of AP-4. Recently, the Drosophila homologue of human AP-4 has been cloned, and shows a high degree of similarity to the human and Caenorhabditis elegans counterparts within the bHLH-Zip domain, the second leucine zipper and a third conserved region of unknown function [22]. In the present work, we show that AP-4 is a ligand for  $\kappa$ -promoter E-boxes, indicating an important and novel role for this ubiquitously expressed regulator in the expression of lineagerestricted genes.

### **EXPERIMENTAL**

### Plasmids

A DNA fragment encoding full-length AP-4 [17] (a gift from Dr R. B. Gaynor, Department of Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75235-8594, U.S.A.) was subcloned into the pGEM<sup>®</sup>-3Z vector (Promega, Madison, WI, U.S.A.). To create an expression plasmid containing a Myc-

Abbreviations used: bHLH, basic helix-loop-helix; bHLH-Zip, bHLH zipper; EMSA, electrophoretic mobility-shift assay; HIV-1, human immunodeficiency virus type-1; lg, immunoglobulin; LPS, lipopolysaccharide; pd, pentadecamer; SV, simian virus.

<sup>1</sup> To whom correspondence should be addressed (e-mail Alaitz.Aranburu@immuno.lu.se)

epitope tagged version of AP-4, AP-4 cDNA was PCR amplified using the 5' primer: 5'-d(GCGGATCCCATATGGAGTATTT-CATGGTGCCCACT) and the 3' T7 primer: 5'd(TAATACG-ACTCACTATAGGG) with the AP-4-pGEM3Z vector as template. The amplified fragment was excised with *Bam*HI and *Eco*RI, and cloned into a *Bam*HI/*Eco*RI-excised MD3 vector resulting in plasmid AP-4MD3. The MD3 vector contains six copies of the myc-epitope inserted into pcDNA3, as described in [14]. The pcDNA3 vector encoding Syrian hamster E47 cDNA (E47-pcDNA3), and the expression plasmid encoding a Mycepitope-tagged version of E47 (E47 cDNA cloned into MD3– E47MD3) are also described in [14].

The 4 × pd-luciferase reporter plasmid was made by inserting a PCR-amplified 4 × pd fragment into the basal *fos* reporter (pGL3*fos*) [14]. The pGL3*fos* contains sequences -56 to +109from the c-*fos* promoter cloned into pGL3Basic (Promega). The 4 × pd-fragment was made using the 5' SP6 primer: 5'd(TAT-TTAGGTGACACTATAG) and the 3' primer: 5'd(ATAAGA-TCTAA TCATGCCTGCA), with the 4 × pdTATACAT-E construct as a template [15]. The PCR product was digested with *Bg*/II, and ligated into the *SacI*/*Bg*/II-digested pGL3*fos*. The 4 × pdpGL3*fos* plasmid was sequenced over the 4 × pd insert.

The  $2 \times (\mu E2\mu E5) fos$  plasmid was made by introducing two copies of the  $\mu E2-\mu E5$ -containing region of the Ig heavy-chain intron enhancer into the pGL3*fos*, as described in [14]. Plasmids MD3, E47-pcDNA3, E47MD3, pGL3*fos* and  $2 \times (\mu E2\mu E5) fos$  were kindly provided by Dr. M. Sigvardsson.

### Nuclear extracts, proteins translated *in vitro* and electrophoretic mobility-shift assay (EMSA)

Nuclear extracts from B-lymphoid (human: Raji, Namalwa, BJAB; murine: K46R and S194) and non-lymphoid (HeLa) cell lines, as well as from lipopolysaccharide (LPS)-stimulated (72 h) primary murine spleen cells were prepared according to Schreiber et al. [23]. In vitro translated AP-4 and E47 were made using the AP-4-pGEM3Z plasmid or the E47-pcDNA3 plasmid, respectively, and the TNT Coupled Reticulocyte Lysate System (Promega) according to the manufacturer's instructions. For EMSAs,  $1 \mu l$  of *in vitro* translated proteins or  $2 \mu l$  of nuclear extract were mixed with 1  $\mu$ g of poly(dI-dC) in 15  $\mu$ l of binding buffer [20 mM phosphate buffer (pH 6.0), 10 mM MgCl<sub>2</sub>, 0.1 mM EDTA, 2 mM dithiothreitol, 0.01 % (v/v) Nonidet P-40, 0.1 mM NaCl, 100  $\mu$ g/ml BSA and 4 % (w/v) Ficoll]. Samples were incubated for 5 min at room temperature before the addition of competitors or antibodies directed against E47 (1 µl, Santa Cruz sc-763 X; Santa Cruz Biotechnology, Santa Cruz, CA, U.S.A.) or AP-4 (kindly provided by Dr R. B. Gaynor), and incubated for a further 15 min at room temperature. <sup>32</sup>P-Labelled probe samples (30000 c.p.m.) were added and the samples were kept at room temperature for 20 min before resolution by PAGE (5% polyacrylamide gel) in TBE [0.09 M Tris/borate (pH 8.0)/2 mM EDTA].

### **Probes and competitors**

<sup>32</sup>P-Labelled or unlabelled oligonucleotides were annealed to unlabelled antisense oligonucleotides and used as probes or competitors respectively. The sense-strand sequence of each of the different oligonucleotides used in EMSA are shown in Figure 2(C).

#### **Cells and transfections**

Cells were cultured in RPMI with glutamine (Gibco BRL) supplemented with 7–8 % fetal-calf serum, 10 mM Hepes, 1 mM

sodium pyruvate and 50  $\mu$ g/ml gentamicin. HeLa cells were transfected with Lipofectin® (Gibco BRL) according to the manufacturer's protocol. Transfections were performed in 24well plates and  $2.5 \times 10^5$  cells/well were grown overnight to 40–60 % confluency. Subsequently, 0.6  $\mu$ g of expression plasmid and  $0.2 \mu g$  of reporter plasmid in 1 ml of serum-free medium (Optimem; Gibco BRL) containing 5 µl of Lipofectin® was added to each well. The transfection mixture was removed after 24 h and replaced with 1 ml of serum-containing medium. After incubation for a further 24 h, the cells were washed once in 1 ml of PBS (Gibco BRL) and harvested into 80 µl of reporter lysis buffer (Promega). The lysate was kept on ice for 10 min and then frozen at -70 °C for > 30 min. A sample (20  $\mu$ l) of the lysate was assayed for luciferase activity using 100  $\mu$ l of luciferase assay reagent (Promega) in a MicroLumat LB96D luminometer (EG & G; Berthold, Pforzheim, Germany). For each experiment, every combination of expression and reporter plasmids was co-transfected in triplicate, and experiments were independently repeated two or three times. Data shown are the mean values for each experiment normalized to the values obtained after co-transfection with reporter plasmid and empty expression plasmid.

### **SDS/PAGE and Western-blot analysis**

SDS/PAGE and electroblotting were performed according to standard procedures [24]. Briefly, the reporter lysis buffer lysate from transfected cells (see above) was denatured in SDS loading buffer containing 100 mM dithiothreitol, and separated by SDS/ PAGE (12 % gel). The proteins were transferred on to a Hybond-C nitrocellulose membrane (Amersham Pharmacia Biotech), which was blocked in 5 % (w/v) skimmed milk in PBST [0.05 %(v/v) Tween in PBS] for 30 min and washed three times for 5 min each time in PBST. Next, the membrane was incubated with a 1:2000 dilution of a mouse anti-myc antibody (Santa Cruz Biotechnology) in PBST and then washed as before. The secondary antibody, a rabbit anti-mouse horseradish peroxidase antibody (Santa Cruz Biotechnology), diluted 1:3750 in PBST, was added for 20 min and then removed by washing. Detection of the antibody-protein complexes by luminescence was performed using the ECL® kit (Amersham Pharmacia Biotech).

### RESULTS

### E-boxes in $\kappa$ promoters

The regulation of Ig transcription using the SP6  $\kappa$  promoter as a model (Figure 1A) has been studied previously [9,10,18]. This mouse  $\kappa$  promoter contains an octamer element [3,25] with a one-base mismatch from the consensus sequence, which is compensated for by octamer flanking nucleotides [26,27]. Furthermore, octamer-dependent, positive transcriptional-control elements are found 5' and 3' of the octamer. Functionally these can be divided into three regions: the pd- $\kappa$ Y region, the CCCT motif and the 3' E-box. The pd- $\kappa$ Y region contains three protein binding motifs: an E-box of the E2A type, an A-T-rich region [3] and the  $\kappa$ Y element [28,29]. These three elements stimulate octamer-induced transcription in concert, since a mutation in any of the elements obliterates the positive effect of the whole region [16]. The CCCT motif and the 3' E-box independently stimulate octamer-dependent transcription [10,18]. The activity of the various subregions of the SP6  $\kappa$  promoter is summarized in Figure 1(B).

With the advent of sequence information from the human  $\kappa$  locus [2], it became evident that the SP6  $\kappa$  promoter represents a composite of a typical human V $\kappa$  I and a V $\kappa$  II subgroup promoter [4]. Hence, the pd element is conserved in the human



### Figure 1 Schematic illustrations of the SP6 $\kappa$ promoter and conservation of E-boxes in $\kappa$ promoters

(A) The elements important for promoter function, and the proteins interacting with them are shown. Abbreviations: CBF-A, CarG-box binding factor-A; EBF, early B-cell factor. (B) Summary of the transcriptional activity of different promoter constructs. Ref, reference. (C) E-box sequences are conserved in human (H) and murine (M)  $\kappa$  promoters. Various human and murine V $\kappa$  subgroups and families are indicated on the left. The conserved E-box core consensus sequences are shown on the right. The sequences shown in bold typeface represent putative AP-4 binding sites.

 $V\kappa$  I promoters, whereas the CCCT element is conserved in  $V\kappa$  II promoters. In addition, the E-boxes in  $\kappa$  promoters are well conserved, both with regard to sequence (5'-CAGCTG-3'; Figure 1C) and to their position relative to the octamer and the TATA box [4]. Given that the E-boxes in  $\kappa$  promoters show this high degree of conservation and functional activity, we favour the view that they are relevant transcriptional control elements for developmentally regulated Ig expression.

### In vitro translated AP-4 and E47 bind to the SP6 $\kappa$ promoter pd element

We have noted previously that, although the SP6  $\kappa$  promoter Eboxes are candidate targets for *E2A* gene products, the results of an investigation of the relevant interaction using nuclear extracts were ambiguous [18]. Since the pd-E-box sequence 5'-CAGCTG-3' is also a putative binding site for the bHLH-Zip protein AP-4 [20], the ability of E47 and/or AP-4 to bind the pd element *in vitro* was investigated. As shown in Figure 2(A), in an EMSA using AP-4 translated *in vitro* and the pd element probe, a complex was formed (lanes 2 and 10). The AP-4 complex was



#### Figure 2 Both AP-4 and E47 bind the pd-element E-box in EMSA

(A) Binding of AP-4, translated *in vitro*, to a radiolabelled pd probe in the absence of competitor oligonucleotides (lanes 2 and 10), or in the presence of different unlabelled competitors as indicated (lanes 3–8 and 11–6). Competitors were added at 100- and 1000-fold molar excess. Lanes 1 and 9 contain reticulocyte lysate without template DNA. (B) Binding of *in vitro*-translated E47 to a radiolabelled pd probe, as in (A). (C) Sequences of the sense strands of the different oligonucleotides used in EMSAs. E-box core sequences are shown underlined. Mutated nucleotides are indicated by lowercase letters.

effectively removed by the addition of an excess of unlabelled pd element (lanes 3 and 4), and by a pd element with a mutated A-T-rich region (pdA-Tmut; lanes 11 and 12). In contrast, a pd element carrying a mutation in the E-box (pdE-box mut; lanes 7 and 8) failed to compete, as did the  $\mu$ E5 oligonucleotide (lanes 5 and 6) and the octamer oligonucleotide (lanes 15 and 16). These results indicate that *in vitro* translated AP-4 binds specifically to the pd-region E-box. We also investigated whether the E-box present in the SP6  $\kappa$  promoter 3'-region interacted with *in vitro* translated AP-4. This was indeed the case, since an unlabelled 3'region oligonucleotide also competed with the AP-4 complex (lanes 13 and 14).

The pd-element E-box was, as expected, also a target for in vitro translated E47 (Figure 2B). A complex formed with E47 and labelled pd probe (lane 2), was efficiently removed by an excess of unlabelled pd element (lanes 3 and 4) but not by pdEbox mut (lanes 5 and 6). The  $\mu$ E5 oligonucleotide (a known target for binding by E47 [30]) was at least as good a competitor as the pd element itself (lanes 7 and 8), and so was a composite oligonucleotide, pd- $\mu$ E5, containing the  $\mu$ E5-motif and the flanking sequences from the pd element (lanes 9 and 10). Thus E47 translated in vitro has affinity for both the pd-element E-box as well as the  $\mu$ E5 motif (Figure 2C). Furthermore, the specificity of the interaction appeared to reside in the E-box core sequence and not in the flanking regions (compare  $\mu$ E5 with pd- $\mu$ E5). AP-4, on the other hand, showed a strong preference for the pd-Ebox, although it also bound the  $\mu$ E5 oligonucleotide when it was used as probe (results not shown).

#### AP-4, but not E47, binds to the pd element in nuclear extracts

Having established that in vitro translated AP-4 and E47 have affinity for SP6  $\kappa$  promoter E-boxes we then investigated whether the pd element was bound by either AP-4 or E47 in nuclear extracts, and a series of gel retardation experiments, using nuclear extracts from human non-lymphoid (HeLa) and B-lymphoid cell lines (Raji, Namalwa and BJAB), were performed. Figure 3(A) shows the results obtained using the Raji cell line with the pd element as a probe; two major gel-retarded complexes were observed. The higher mobility band corresponds to CArG-box binding factor-A [31], whereas the lower mobility band showed a similar pattern of competition as in vitro translated AP-4 when using the same set of competitors. The addition of an excess of the unlabelled pd element (Figure 3A, lanes 2 and 3), the pdA-T mut (lanes 9 and 10) or the 3' E-box (lanes 11 and 12) inhibited binding of the nuclear factor. Neither pdE-box mut (lanes 6 and 7) nor the octamer oligonucleotide (lanes 13 and 14) prevented formation of the specific complex, whereas  $\mu E5$  competed slightly for complex formation in nuclear extracts (lanes 4 and 5). It should be noted that  $\mu E5$  strongly inhibited complex formation between in vitro translated E47 and the pd element probe, whereas this was not the case when using in vitro translated AP-4 (compare Figure 2B, lanes 7 and 8, and Figure 2A, lanes 5 and 6). Similar results were obtained using nuclear extracts from the Namalwa, BJAB and HeLa cell lines (results not shown).

To unequivocally identify the pd-element binding factor, the specific complex was further analysed by the addition of antibodies. As shown in Figure 3(B), a polyclonal antibody against AP-4 [17] prevented formation of the complex (lanes 2-4), whereas an antibody directed against E47 did not (lane 5). Since both in vitro translated AP-4 and E47 could bind to the same site, but only AP-4 appeared to be involved in complex formation in nuclear extracts, we next addressed the question whether E47 was present in the nuclear extract preparations. The  $\mu E5$  probe with Raji nuclear extracts as a source of protein was used in an EMSA. As shown in Figure 3(C), three gel-retarded complexes were obtained. The addition of antibodies against E47 (lane 3) and AP-4 (lane 2) showed that the slower migrating complex contained E47, whereas the faster migrating complex contained AP-4. We conclude from these data that AP-4 is the preferred pd-element ligand in nuclear extracts, even in the presence of E47, which has an intrinsic affinity for the pd-element E-box (Figure 2B).

### AP-4 also binds to the 3' E-box in the SP6 $\kappa$ promoter

Figures 2(A) and 3(A) show that the addition of an excess of the 3' E-box oligonucleotide inhibited binding of AP-4 to the pd



#### Figure 3 AP-4, but not E47, binds the pd-element E-box in nuclear extracts derived from the Raji cell line

(A) EMSA with nuclear extracts from the Raji (human B-cell lymphoma) cell line as a source of protein and a radiolabelled pd-element probe. Various unlabelled competitors, as indicated, were added in 100- and 1000-fold molar excess. (B) EMSA performed with Raji nuclear extract and a pd-element probe (lane 1), and with the addition of polyclonal antibodies against AP-4 ( $\alpha$ -AP4; lanes 2–4, antibody diluted 1:10, 1:5, 1:2 respectively) or E47 ( $\alpha$ -E47; lane 5). (C) EMSA with nuclear extracts from the Raji cell line as a source of protein and a radiolabelled  $\mu$ E5 probe, showing that the nuclear extract contains E47. Lane 1 shows the three gel-retarded complexes formed with the  $\mu$ E5 probe; the lower mobility band was beent after the addition of anti-E47 antibody ( $\alpha$ -E47; lane 3), whereas the highest mobility band was removed by the addition of AP-4 antibody ( $\alpha$ -AP4; lane 2).

probe, indicating that the 3' E-box might also be a binding site for AP-4. In order to confirm this, we performed EMSAs with human B-cell lymphoma nuclear extracts and a labelled 3' E-box probe (Figure 4A). Two complexes were formed, a specific lowmobility band and an non-specific band with higher mobility. Formation of the specific complex was inhibited by the addition of an excess of unlabelled 3' E-box (lanes 2 and 3) and by the pd element (lanes 4 and 5), whereas addition of  $\mu$ E5 (lanes 6 and 7), pdE-boxmut (lane 8) or the octamer oligonucleotide (lane 9) did not compete for binding. The low-mobility band was shown to contain AP-4, since its formation was prevented by the addition of an anti-AP-4 antibody (Figure 4B, lanes 2–4) but not by an anti-E47 antibody (lane 5). In conclusion, these results demonstrate that AP-4 also is the preferred ligand for the SP6  $\kappa$  3' Ebox.



## Figure 4 AP-4 binds the E-box present in the SP6 $\kappa$ promoter 3' region: EMSA with nuclear extracts from the Raji cell line and radiolabelled 3' E-box probe

(A) The lower mobility band was removed by addition of a 200- or 1000-fold molar excess of unlabelled 3' E-box (lanes 2 and 3) and pd element (lanes 4 and 5). The same concentration of the  $\mu$ E5 element did not affect the binding of the nuclear factor to the template (lanes 6 and 7). In a similar manner, a 1000-fold molar excess of the pd element with a disrupted E-box (pdE-boxmut; lane 8) and the octamer (lane 9) failed to compete. (B) EMSA with Raji nuclear extracts and the 3' E-box probe (lane 1), and with the addition of an AP-4 antibody ( $\alpha$ -AP4; lanes 2–4, antibody diluted 1:10, 1:5, 1:2 respectively), or an antibody against E47 ( $\alpha$ -E47; lane 5).

### AP-4 in nuclear extracts from murine B-cell lines binds to the pd element

The antibody against AP-4 was raised against the human AP-4 protein [17], and therefore all our initial experiments were made using nuclear extracts derived from human B-cell lines. However,



Figure 5 Complex between AP-4 translated *in vitro* and a pd element probe has similar mobility to the complex detected in nuclear extracts from the Raji and S194 cell lines

EMSA using the pd element as a probe with AP-4 translated *in vitro* (IVT AP-4; lane 1), nuclear extracts from the Raji (lane 2) or S194 cell lines (lanes 3–5). In lanes 4 and 5, antibodies against AP-4 ( $\alpha$ -AP4) or E47 ( $\alpha$ -E47) respectively were added.

since our model promoter is the murine SP6  $\kappa$  promoter, we also tested for complex formation using the pd element and nuclear extracts derived from the murine lymphoid cell lines K46R (a Bcell lymphoma) and S194 (a plasmacytoma), as well as from primary LPS-stimulated murine spleen cells. Figure 5 shows the results of an EMSA using the S194 plasmacytoma cell line. A complex was detected (lane 3) with similar electrophoretic mobility to the complex formed using in vitro translated AP-4 (lane 1), and to that formed with nuclear extracts from the human Raji cell line (lane 2). Moreover, the S194 complex was removed by the addition of the anti-AP-4 antibody (lane 4) but not by the anti-E47 antibody (lane 5). Similar results were obtained with nuclear extracts from K46R and LPS-stimulated spleen cells (results not shown), indicating that AP-4, and not E47 or any other bHLH protein, was the preferred protein interacting with the pd element in murine B cells.

### Ectopically expressed AP-4 does not transactivate a pd-element reporter construct

AP-4 was initially identified as an SV40 enhancer binding factor capable of stimulating SV40 transcription *in vitro*, and it has been reported to bind several viral and cellular enhancers. However, not much is known about the function of AP-4 in promoting transcription, in contrast to the well-known transactivation properties of E47. We wanted to compare the ability of AP-4 and E47 to transactivate a reporter construct containing the pd element as a regulatory element. We therefore made a reporter plasmid carrying four copies of the pd element linked to the c-*fos* minimal promoter and a luciferase reporter gene. This reporter was transiently co-transfected into HeLa cells, together







(A) HeLa cells were co-transfected with plasmids expressing either AP-4 or E47 or empty expression vector (pcDNA3) and a luciferase reporter plasmid carrying either two copies of the  $\mu$ E2- $\mu$ E5 sites [2 × ( $\mu$ E2 $\mu$ E5)], linked to a minimal *fos* promoter or a multimerized pd element (4 × pd). Fold induction was calculated relative to the level of luciferase expression obtained with pcDNA3. (B) Western-blot analysis of lysates used to measure luciferase activity as in (A), showing that Myc-tagged AP-4 is expressed equally well as the Myc-tagged E47. Lysates were from co-transfections using the indicated expression and reporter plasmids. The proteins were detected with a Myc antibody and the arrows indicate the positions of Myc-tagged AP-4 and Myc-tagged E47 respectively. Molecular-mass standards are indicated on the right.

with an expression vector encoding Myc-tagged versions of either AP-4 or E47. The ability of AP-4 and E47 to transactivate a luciferase reporter carrying two copies each of the  $\mu$ E2 and  $\mu$ E5 motifs as regulatory element was also analysed. As shown in Figure 6(A), E47 transactivated the pd-construct poorly (about 10-fold), whereas the  $\mu$ E2- $\mu$ E5-construct was very efficiently activated (200-fold). In contrast, AP-4 did not transactivate any of the reporter constructs. The Myc-tagged versions of both AP-4 and E47 were efficiently expressed in the transfected cells, as seen in Figure 6(B), which shows a Western-blot of the same lysates as those used for assaying luciferase activity in a representative transfection experiment. In addition, the Myc-tagged version of AP-4 bound the pd probe efficiently in an EMSA (results not shown). In addition, co-transfection experiments using untagged AP-4 were performed and similar results to those where the Myc-tagged version was used were obtained (results not shown). Thus we conclude that, at least in the context of the pd element, AP-4 is not a transactivator but must act via alternate mechanisms (see below). The low level of activation induced by epitope-tagged E47 on the 4×pd-reporter when compared with its effect on the  $\mu$ E2- $\mu$ E5-construct is probably due to E47 being excluded from the pd-E-box site by endogenous AP-4, since no binding of E47 to the pd probe was detected in EMSAs when using nuclear exctracts as a source of protein (Figure 3B). In addition, we did not detect E47 binding to the pd probe in nuclear extracts prepared after transfection of HeLa cells with the E47 expression plasmid, whereas binding to the  $\mu$ E5 probe was readily detected (results not shown).

### DISCUSSION

In this study our goal was to identify the ligand for the two Eboxes present in the SP6  $\kappa$  promoter. Using synthetic mutant or wild-type pd element oligonucleotides, in addition to a wild-type 3' E-box oligonucleotide in EMSA experiments, we have shown that the bHLH-Zip protein AP-4 interacts in a specific fashion with both E-boxes. Both in vitro translated AP-4 and nuclearextract-derived AP-4 exhibited similar competition patterns and, in nuclear extracts, the major protein-DNA complex formed was shown to contain AP-4 when specific antibodies were used. Experiments were carried out with human B-cell lymphomas (Raji, Namalwa and BJAB) and with several murine cell lines and similar results were obtained. The majority of the E-boxes found in  $\kappa$  promoters are putative AP-4 binding sites (Figure 1C), and it has been speculated that the original  $\kappa$  gene promoter contained a TATA-box, an octamer element and possibly an Ebox [32]. Since the latter element is well conserved in  $\kappa$  promoters [4], and our findings show that AP-4 binds to both E-boxes in the SP6  $\kappa$  promoter, we would like to propose AP-4 as the major ligand for  $\kappa$  promoter E-boxes.

It should be noted that the pd element is a weak stimulatory element when present as four copies in a minimal promoter [15], indicating that none of the pd-element ligands should be strong transcriptional activators. Furthermore, the activity of each of the SP6  $\kappa$  co-stimulatory elements is octamer-dependent, precluding the possibility of a strong activator binding to any of these sites and thereby overuling the function of the octamerbinding proteins. This functional profile of pd interacting proteins fits nicely with the transfection data shown in the present study, where no stimulation was seen with AP-4 but the potent activator function of E47 disqualified it as a pd-element ligand, given that all  $\kappa$  promoter transcription should be octamer-dependent [6-8,10]. In vitro translated E47 showed a robust interaction with the pd probe in EMSAs, whereas no interaction between E47 and the pd probe was detected when nuclear extracts were used. This might be due to AP-4 being more abundantly expressed than E47 and/or having a higher intrinsic affinity for the pd element.

AP-4 has been shown to interact with sites in both promoter and enhancer regions of viral and cellular enhancers. For

In conclusion, we have provided evidence that the ubiquitous transcription factor AP-4 is the major E-box ligand within  $\kappa$  promoters. This finding would indicate that there is a division of labour within the Ig loci, where the *E2A* gene products primarily interact with and regulate enhancer elements, whereas AP-4 would be the primary promoter E-box ligand. The further consequences of this finding with regard to developmental regulation of the Ig loci and communication between enhancer and promoter elements remain to be clarified.

We thank Dr R.B. Gaynor for the gift of AP-4 cDNA and the anti-AP-4 antibody, Dr. M. Sigvardsson for the gift of various reporter plasmids and E47 expression constructs, Dr. M. Bemark for useful discussions, and D. Liberg for a critical reading of the manuscript. This work was supported by grants from the Swedish Medical Research Council, the Swedish Cancer Society, the Swedish Natural Sciences Research Council, and by the Basque Government through a fellowship (Programa de Formación de Investigadores del Departamento de Educación, Universidades e Investigación) to A.A.

### REFERENCES

- Strohal, R., Helmberg, A., Kroemer, G. and Kofler, R. (1989) Mouse Vk gene classification by nucleic acid sequence similarity. Immunogenetics 30, 475–493
- 2 Schäble, K. F. and Zachau, H.-G. (1993) The variable genes of the human immunoglobulin κ locus. Biol. Chem. Hoppe-Seyler 374, 1001–1022

- 3 Falkner, F. G. and Zachau, H. G. (1984) Correct transcription of an immunoglobulin κ gene requires an upstream fragment containing conserved sequence elements. Nature (London) **310**, 71–74
- 4 Bemark, M., Liberg, D. and Leanderson, T. (1998) Conserved sequence elements in κ promoters from mice and humans: implications for transcriptional regulation and repertoire expression. Immunogenetics 47, 183–195
- 5 Matthias, P. (1998) Lymphoid-specific transcription mediated by the conserved octamer site: who is doing what? Semin. Immunol. 10, 155–163
- 6 Bergman, Y., Rice, D., Grosschedl, R. and Baltimore, D. (1984) Two regulatory elements for immunoglobulin κ light chain gene expression. Proc. Natl. Acad. Sci. U.S.A. 81, 7041–7045
- 7 Wirth, T., Staudt, L. and Baltimore, D. (1987) An octamer oligonucleotide upstream of a TATA motif is sufficient for lymphoid-specific promoter activity. Nature (London) 329, 174–178
- 8 Eaton, S. and Calame, K. (1987) Multiple DNA sequence elements are necessary for the function of an immunoglobulin heavy chain promoter. Proc. Natl. Acad. Sci. U.S.A. 84, 7634–7638
- 9 Sigvardsson, M., Bemark, M. and Leanderson, T. (1995) Stimulation of κ transcription by a decamer-dependent, synergistic mechanism. Eur. J. Immunol. 25, 298–301
- 10 Högborn, E., Magnusson, A.-C. and Leanderson, T. (1991) Functional modularity in the SP6  $\kappa$  promoter. Nucleic Acids Res. **19**, 4347–4354
- 11 Blackwell, T. K. and Weintraub, H. (1990) Differences and similarities in DNA-binding preferences of MyoD and E2A protein complexes revealed by binding site selection. Science 250, 1104–1110
- 12 Schlissel, M., Voronova, A. and Baltimore, D. (1991) Helix–loop–helix transcription factor E47 activates germ-line immunoglobulin heavy-chain gene transcription and rearrangement in a pre-T-cell line. Genes Dev. 5, 1367–1376
- 13 Choi, J. K., Shen, C. P., Radomska, H. S., Eckhardt, L. A. and Kadesch, T. (1996) E47 activates the Ig-heavy chain and TdT loci in non-B cells. EMBO J. 15, 5014–5021
- 14 Sigvardsson, M. (2000) Overlapping expression of early B-cell factor and basic helix–loop–helix proteins as a mechanism to dictate B-lineage-specific activity of the  $\lambda$ 5 promoter. Mol. Cell. Biol. **20**, 3640–3654
- 15 Sigvardsson, M., Bemark, M. and Leanderson, T. (1995) Pentadecamer-binding proteins: definition of two independent protein-binding sites needed for functional activity. Mol. Cell. Biol. **15**, 1343–1352
- 16 Bemark, M. and Leanderson, T. (1997) Diverse transcription factors are involved in the quantitative regulation of transcriptional activation of κ promoters. Eur. J. Immunol. 27, 1308–1318
- 17 Ou, S. H., Garcia-Martinez, L. F., Paulssen, E. J. and Gaynor, R. B. (1994) Role of flanking E box motifs in human immunodeficiency virus type 1 TATA element function. J. Virol. 68, 7188–7199
- 18 Liberg, D., Sigvardsson, M., Bemark, M. and Leanderson, T. (1998) Differentiationspecific, octamer-dependent costimulation of κ transcription. J. Immunol. 160, 3899–3907
- 19 Hu, Y. F., Luscher, B., Admon, A., Mermod, N. and Tjian, R. (1990) Transcription factor AP-4 contains multiple dimerization domains that regulate dimer specificity. Genes Dev. 4, 1741–1752
- 20 Mermod, N., Williams, T. J. and Tjian, R. (1988) Enhancer binding factors AP-4 and AP-1 act in concert to activate SV40 late transcription in vitro. Nature (London) 332, 557-561
- 21 Littlewood, T. and Evan, G. (1995) Transcription factors 2: helix-loop-helix. In Protein Profile. pp. 632–635, Academic Press, Chichester
- 22 King-Jones, K., Korge, G. and Lehmann, M. (1999) The helix–loop–helix proteins dAP-4 and daughterless bind both *in vitro* and *in vivo* to SEBP3 sites required for transcriptional activation of the Drosophila gene Sgs-4. J. Mol. Biol. **291**, 71–82
- 23 Schreiber, E., Matthias, P., Muller, M. M. and Schaffner, W. (1989) Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells. Nucleic Acids Res. **17**, 6419
- 24 Sambrook, J., Fritsch, E. F. and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual, 2nd edn, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
- 25 Parslow, T. G., Blair, D. L., Murphy, W. J. and Granner, D. K. (1984) Structure of the 5' ends of immunoglobulin genes: a novel conserved sequence. Proc. Natl. Acad. Sci. U.S.A. 81, 2650–2654
- 26 Sigvardsson, M. and Leanderson, T. (1994) Positive transcriptional control elements within the SP6  $\kappa$  promoter decamer 3' flanking sequence. Mol. Immunol. **31**, 1005–1016
- 27 Liberg, D., Sigvardsson, M. and Leanderson, T. (1997) Oct proteins are qualitative rather than quantitative regulators of  $\kappa$  transcription. Mol. Immunol. **34**, 979–986
- 28 Atchison, M. L., Delmas, V. and Perry, R. P. (1990) A novel upstream element compensates for an ineffectual octamer motif in an immunoglobulin V κ promoter. EMBO J. 9, 3109–3117

- 29 Schwarzenbach, H., Newell, J. W. and Matthias, P. (1995) Involvement of the Ets family factor PU.1 in the activation of immunoglobulin promoters. J. Biol. Chem. 270, 898–907
- 30 Murre, C., McCaw, P. S. and Baltimore, D. (1989) A new DNA binding and dimerization motif in immunoglobulin enhancer binding, daughterless, MyoD, and myc proteins. Cell 56, 777–783
- 31 Bemark, M., Olsson, H., Heinegard, D. and Leanderson, T. (1998) Purification and characterization of a protein binding to the SP6 κ promoter. A potential role for CArG-box binding factor-A in κ transcription. J. Biol. Chem. 273, 18881–18890
- 32 Bemark, M. and Leanderson, T. (1999) Promotion of immunoglobulin gene transcription. Immunologist **7**, 177–183
- 33 Fodor, E., Weinrich, S. L., Meister, A., Mermod, N. and Rutter, W. J. (1991) A pancreatic exocrine cell factor and AP4 bind overlapping sites in the amylase 2A enhancer. Biochemistry **30**, 8102–8108

Received 23 August 2000/23 November 2000; accepted 2 January 2001

- 34 Comb, M., Mermod, N., Hyman, S. E., Pearlberg, J., Ross, M. E. and Goodman, H. M. (1988) Proteins bound at adjacent DNA elements act synergistically to regulate human proenkephalin cAMP inducible transcription. EMBO J. 7, 3793–3805
- 35 Friez, M., Hermansen, R. and Milavetz, B. (1999) Chromatin structure of the simian virus 40 late promoter: a deletional analysis. J. Virol. **73**, 1990–1997
- 36 Unk, I., Kiss-Toth, E. and Boros, I. (1994) Transcription factor AP-4 participates in activation of bovine leukemia virus long terminal repeat by p34 Tax. Nucleic Acids Res. 22, 4872–4875
- 37 Badinga, L., Song, S., Simmen, R. C. and Simmen, F. A. (1998) A distal regulatory region of the insulin-like growth factor binding protein-2 (IGFBP-2) gene interacts with the basic helix–loop–helix transcription factor, AP-4. Endocrine 8, 281–289
- 38 Cui, Y., Narayanan, C. S., Zhou, J. and Kumar, A. (1998) Exon-I is involved in positive as well as negative regulation of human angiotensinogen gene expression. Gene 224, 97–107